Hematology

Vadadustat tablets are now approved for the treatment of anemia due to CKD in adults who have been receiving dialysis for ≥ 3 months.

A new analysis summarized evidence on the effects of allogeneic HSCT on SCD-related organ dysfunction in pediatric and adult patients with SCD.

A posthoc analysis of two phase 3 trials identified multiple independent factors associated with better response to vadadustat in patients with anemia.

A study in China identified a negative and non-linear relationship between hemoglobin levels and a renal composite end point in patients with DKD.

Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.

Measurement of reticulocyte hemoglobin equivalent is cost-effective and could be a useful marker of iron deficiency in acute decompensated heart failure.

Results from the PHEDRE study show nitrous oxide in a gas mixture for pain was not problematic for most patients with sickle cell disease in France.

Iron deficiency, independent of anemia, may be a potentially modifiable target to improve patient-reported outcomes after kidney transplantation.

A cross-sectional analysis of nine low- and middle-income countries revealed few statistically significant associations between anemia and early childhood development.

Iptacopan monotherapy improved hematologic outcomes in both anti-C5–treated patients with persistent anemia and those not treated with complement inhibitors across two phase 3 trials.

In a registry-based analysis, more hospitalized children with SCD and COVID-19 had severe infection requiring supplemental oxygen, compared with the general population.

The 2016 CDC guidelines led to significant decreases in opioid prescriptions and an increase in pain-related healthcare utilization for people with sickle cell disease.

An analysis of an FDA adverse event database found thrombotic adverse events were more frequently reported with emicizumab than those of FVIII products.

Patients in France with hemophilia A who switched their FVIII replacement treatment trended towards fewer bleeding events and articular non-bleeding events requiring hospitalization.

Iron deficiency marks more than a comorbidity in heart failure, with adverse manifestations, including anemia and a higher risk of mortality, influencing the clinical trajectory of patients with HFrEF.

Initiation of SGLT2 inhibitors reduced the risk of composite anemia outcomes, compared with GLP-1 RA, among patients with type 2 diabetes and CKD.

In a post hoc analysis of the ACCT-2 study, a risk profile using simple hematologic parameters identified patients hospitalized with COVID-19 who benefited most from baricitinib treatment.

Introduction of curated materials to assist clinicians was linked to better rates of screening and treatment of iron deficiency anemia among patients with heart failure.

An ancillary study of the phase 2 HOPE-KIDS 1 trial revealed voxelotor is associated with reduced sickling and hemolysis in children with SCD.

More than half of older patients admitted to geriatric units in France had iron deficiency, including patients without anemia.

Rusfertide maintained a hematocrit of <45% and reduced or eliminated the use of phlebotomy in patients with polycythemia vera.

A meta-analysis revealed a higher prevalence of abnormal ECG findings in individuals with SCD compared to those without the disease.

A meta-analysis of four RCTs found Iron isomaltoside ferumoxytol is both effective and safe to treat iron deficiency anemia.

Voxelotor decreases oxygen extraction fraction and cerebral blood flow towards levels observed in healthy children.

No concerning patterns of long-term or increasing opioid use were observed within 3 years after first opioid prescription in opioid-naive children with SCD.